Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease

Manu Sharma, Demetrius M. Maraganore, John P A Ioannidis, Olaf Riess, Jan O. Aasly, Grazia Annesi, Nadine Abahuni, Anna Rita Bentivoglio, Alexis Brice, Christine Van Broeckhoven, Marie Christine Chartier-Harlin, Alain Destée, Ana Djarmati, Alexis Elbaz, Matthew Farrer, Carlo Ferrarese, J. Mark Gibson, Suzana Gispert, Nobutaka Hattori, Barbara Jasinska-MygaChristine Klein, Suzanne Lesage, Timothy Lynch, Peter Lichtner, Jean Charles Lambert, Anthony E. Lang, George D. Mellick, Francesa De Nigris, Grzegorz Opala, Aldo Quattrone, Chiara Riva, Ekaterina Rogaeva, Owen A Ross, Wataru Satake, Peter A. Silburn, Jessie Theuns, Tatsushi Toda, Hiroyuki Tomiyama, Ryan J. Uitti, Karin Wirdefeldt, Zbigniew K Wszolek, Thomas Gasser, Rejko Krüger

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Sepiapterin reductase (SPR) gene is an enzyme which catalyses the final step of tetrahydrobiopterin synthesis (BH4) and was implicated in Parkinson's disease (PD) pathogenesis as a candidate gene for PARK3 locus. A number of studies yielded association of the PARK3 locus with PD, and SPR knockout mice were shown to display parkinsonian features. To evaluate the role of SPR gene polymorphisms in diverse populations in PD, we performed collaborative analyses in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. A total of 5 single nucleotide polymorphisms (3 in the promoter region and 2 in the 3′ untranslated region [UTR]) were genotyped. Fixed as well as random effect models were used to provide summary risk estimates of SPR variants. A total of 19 sites provided data for 6547 cases and 9321 controls. Overall odds ratio estimates varied from 0.92 to 1.01. No overall association with the SPR gene using either fixed effect or random effect model was observed in the studied population. I 2 Metric varied from 0% to 36.2%. There was some evidence for an association for participants of North European/Scandinavian descent with the strongest signal for rs1876487 (odds ratio = 0.82; p value = 0.003). Interestingly, families which were used to map the PARK3 locus, have Scandinavian ancestry suggesting a founder effect. In conclusion, this large association study for the SPR gene revealed no association for PD worldwide. However, taking the initial mapping of the PARK3 into account, the role of a population-specific effect warrants consideration in future studies.

Original languageEnglish (US)
JournalNeurobiology of Aging
Volume32
Issue number11
DOIs
StatePublished - Nov 2011

Fingerprint

sepiapterin reductase
Parkinson Disease
Genes
Odds Ratio
Population
Founder Effect
Molecular Epidemiology
3' Untranslated Regions
Genetic Promoter Regions
Knockout Mice
Single Nucleotide Polymorphism

Keywords

  • PARK3
  • Parkinson disease
  • PD genetic studies
  • PD-GWAS
  • SPR

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Aging
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Sharma, M., Maraganore, D. M., Ioannidis, J. P. A., Riess, O., Aasly, J. O., Annesi, G., ... Krüger, R. (2011). Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. Neurobiology of Aging, 32(11). https://doi.org/10.1016/j.neurobiolaging.2011.05.024

Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. / Sharma, Manu; Maraganore, Demetrius M.; Ioannidis, John P A; Riess, Olaf; Aasly, Jan O.; Annesi, Grazia; Abahuni, Nadine; Bentivoglio, Anna Rita; Brice, Alexis; Van Broeckhoven, Christine; Chartier-Harlin, Marie Christine; Destée, Alain; Djarmati, Ana; Elbaz, Alexis; Farrer, Matthew; Ferrarese, Carlo; Gibson, J. Mark; Gispert, Suzana; Hattori, Nobutaka; Jasinska-Myga, Barbara; Klein, Christine; Lesage, Suzanne; Lynch, Timothy; Lichtner, Peter; Lambert, Jean Charles; Lang, Anthony E.; Mellick, George D.; De Nigris, Francesa; Opala, Grzegorz; Quattrone, Aldo; Riva, Chiara; Rogaeva, Ekaterina; Ross, Owen A; Satake, Wataru; Silburn, Peter A.; Theuns, Jessie; Toda, Tatsushi; Tomiyama, Hiroyuki; Uitti, Ryan J.; Wirdefeldt, Karin; Wszolek, Zbigniew K; Gasser, Thomas; Krüger, Rejko.

In: Neurobiology of Aging, Vol. 32, No. 11, 11.2011.

Research output: Contribution to journalArticle

Sharma, M, Maraganore, DM, Ioannidis, JPA, Riess, O, Aasly, JO, Annesi, G, Abahuni, N, Bentivoglio, AR, Brice, A, Van Broeckhoven, C, Chartier-Harlin, MC, Destée, A, Djarmati, A, Elbaz, A, Farrer, M, Ferrarese, C, Gibson, JM, Gispert, S, Hattori, N, Jasinska-Myga, B, Klein, C, Lesage, S, Lynch, T, Lichtner, P, Lambert, JC, Lang, AE, Mellick, GD, De Nigris, F, Opala, G, Quattrone, A, Riva, C, Rogaeva, E, Ross, OA, Satake, W, Silburn, PA, Theuns, J, Toda, T, Tomiyama, H, Uitti, RJ, Wirdefeldt, K, Wszolek, ZK, Gasser, T & Krüger, R 2011, 'Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease', Neurobiology of Aging, vol. 32, no. 11. https://doi.org/10.1016/j.neurobiolaging.2011.05.024
Sharma, Manu ; Maraganore, Demetrius M. ; Ioannidis, John P A ; Riess, Olaf ; Aasly, Jan O. ; Annesi, Grazia ; Abahuni, Nadine ; Bentivoglio, Anna Rita ; Brice, Alexis ; Van Broeckhoven, Christine ; Chartier-Harlin, Marie Christine ; Destée, Alain ; Djarmati, Ana ; Elbaz, Alexis ; Farrer, Matthew ; Ferrarese, Carlo ; Gibson, J. Mark ; Gispert, Suzana ; Hattori, Nobutaka ; Jasinska-Myga, Barbara ; Klein, Christine ; Lesage, Suzanne ; Lynch, Timothy ; Lichtner, Peter ; Lambert, Jean Charles ; Lang, Anthony E. ; Mellick, George D. ; De Nigris, Francesa ; Opala, Grzegorz ; Quattrone, Aldo ; Riva, Chiara ; Rogaeva, Ekaterina ; Ross, Owen A ; Satake, Wataru ; Silburn, Peter A. ; Theuns, Jessie ; Toda, Tatsushi ; Tomiyama, Hiroyuki ; Uitti, Ryan J. ; Wirdefeldt, Karin ; Wszolek, Zbigniew K ; Gasser, Thomas ; Krüger, Rejko. / Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. In: Neurobiology of Aging. 2011 ; Vol. 32, No. 11.
@article{b32b1d7c9dda4c5481d0f35f4bec8b87,
title = "Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease",
abstract = "Sepiapterin reductase (SPR) gene is an enzyme which catalyses the final step of tetrahydrobiopterin synthesis (BH4) and was implicated in Parkinson's disease (PD) pathogenesis as a candidate gene for PARK3 locus. A number of studies yielded association of the PARK3 locus with PD, and SPR knockout mice were shown to display parkinsonian features. To evaluate the role of SPR gene polymorphisms in diverse populations in PD, we performed collaborative analyses in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. A total of 5 single nucleotide polymorphisms (3 in the promoter region and 2 in the 3′ untranslated region [UTR]) were genotyped. Fixed as well as random effect models were used to provide summary risk estimates of SPR variants. A total of 19 sites provided data for 6547 cases and 9321 controls. Overall odds ratio estimates varied from 0.92 to 1.01. No overall association with the SPR gene using either fixed effect or random effect model was observed in the studied population. I 2 Metric varied from 0{\%} to 36.2{\%}. There was some evidence for an association for participants of North European/Scandinavian descent with the strongest signal for rs1876487 (odds ratio = 0.82; p value = 0.003). Interestingly, families which were used to map the PARK3 locus, have Scandinavian ancestry suggesting a founder effect. In conclusion, this large association study for the SPR gene revealed no association for PD worldwide. However, taking the initial mapping of the PARK3 into account, the role of a population-specific effect warrants consideration in future studies.",
keywords = "PARK3, Parkinson disease, PD genetic studies, PD-GWAS, SPR",
author = "Manu Sharma and Maraganore, {Demetrius M.} and Ioannidis, {John P A} and Olaf Riess and Aasly, {Jan O.} and Grazia Annesi and Nadine Abahuni and Bentivoglio, {Anna Rita} and Alexis Brice and {Van Broeckhoven}, Christine and Chartier-Harlin, {Marie Christine} and Alain Dest{\'e}e and Ana Djarmati and Alexis Elbaz and Matthew Farrer and Carlo Ferrarese and Gibson, {J. Mark} and Suzana Gispert and Nobutaka Hattori and Barbara Jasinska-Myga and Christine Klein and Suzanne Lesage and Timothy Lynch and Peter Lichtner and Lambert, {Jean Charles} and Lang, {Anthony E.} and Mellick, {George D.} and {De Nigris}, Francesa and Grzegorz Opala and Aldo Quattrone and Chiara Riva and Ekaterina Rogaeva and Ross, {Owen A} and Wataru Satake and Silburn, {Peter A.} and Jessie Theuns and Tatsushi Toda and Hiroyuki Tomiyama and Uitti, {Ryan J.} and Karin Wirdefeldt and Wszolek, {Zbigniew K} and Thomas Gasser and Rejko Kr{\"u}ger",
year = "2011",
month = "11",
doi = "10.1016/j.neurobiolaging.2011.05.024",
language = "English (US)",
volume = "32",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease

AU - Sharma, Manu

AU - Maraganore, Demetrius M.

AU - Ioannidis, John P A

AU - Riess, Olaf

AU - Aasly, Jan O.

AU - Annesi, Grazia

AU - Abahuni, Nadine

AU - Bentivoglio, Anna Rita

AU - Brice, Alexis

AU - Van Broeckhoven, Christine

AU - Chartier-Harlin, Marie Christine

AU - Destée, Alain

AU - Djarmati, Ana

AU - Elbaz, Alexis

AU - Farrer, Matthew

AU - Ferrarese, Carlo

AU - Gibson, J. Mark

AU - Gispert, Suzana

AU - Hattori, Nobutaka

AU - Jasinska-Myga, Barbara

AU - Klein, Christine

AU - Lesage, Suzanne

AU - Lynch, Timothy

AU - Lichtner, Peter

AU - Lambert, Jean Charles

AU - Lang, Anthony E.

AU - Mellick, George D.

AU - De Nigris, Francesa

AU - Opala, Grzegorz

AU - Quattrone, Aldo

AU - Riva, Chiara

AU - Rogaeva, Ekaterina

AU - Ross, Owen A

AU - Satake, Wataru

AU - Silburn, Peter A.

AU - Theuns, Jessie

AU - Toda, Tatsushi

AU - Tomiyama, Hiroyuki

AU - Uitti, Ryan J.

AU - Wirdefeldt, Karin

AU - Wszolek, Zbigniew K

AU - Gasser, Thomas

AU - Krüger, Rejko

PY - 2011/11

Y1 - 2011/11

N2 - Sepiapterin reductase (SPR) gene is an enzyme which catalyses the final step of tetrahydrobiopterin synthesis (BH4) and was implicated in Parkinson's disease (PD) pathogenesis as a candidate gene for PARK3 locus. A number of studies yielded association of the PARK3 locus with PD, and SPR knockout mice were shown to display parkinsonian features. To evaluate the role of SPR gene polymorphisms in diverse populations in PD, we performed collaborative analyses in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. A total of 5 single nucleotide polymorphisms (3 in the promoter region and 2 in the 3′ untranslated region [UTR]) were genotyped. Fixed as well as random effect models were used to provide summary risk estimates of SPR variants. A total of 19 sites provided data for 6547 cases and 9321 controls. Overall odds ratio estimates varied from 0.92 to 1.01. No overall association with the SPR gene using either fixed effect or random effect model was observed in the studied population. I 2 Metric varied from 0% to 36.2%. There was some evidence for an association for participants of North European/Scandinavian descent with the strongest signal for rs1876487 (odds ratio = 0.82; p value = 0.003). Interestingly, families which were used to map the PARK3 locus, have Scandinavian ancestry suggesting a founder effect. In conclusion, this large association study for the SPR gene revealed no association for PD worldwide. However, taking the initial mapping of the PARK3 into account, the role of a population-specific effect warrants consideration in future studies.

AB - Sepiapterin reductase (SPR) gene is an enzyme which catalyses the final step of tetrahydrobiopterin synthesis (BH4) and was implicated in Parkinson's disease (PD) pathogenesis as a candidate gene for PARK3 locus. A number of studies yielded association of the PARK3 locus with PD, and SPR knockout mice were shown to display parkinsonian features. To evaluate the role of SPR gene polymorphisms in diverse populations in PD, we performed collaborative analyses in the Genetic Epidemiology of Parkinson Disease (GEO-PD) Consortium. A total of 5 single nucleotide polymorphisms (3 in the promoter region and 2 in the 3′ untranslated region [UTR]) were genotyped. Fixed as well as random effect models were used to provide summary risk estimates of SPR variants. A total of 19 sites provided data for 6547 cases and 9321 controls. Overall odds ratio estimates varied from 0.92 to 1.01. No overall association with the SPR gene using either fixed effect or random effect model was observed in the studied population. I 2 Metric varied from 0% to 36.2%. There was some evidence for an association for participants of North European/Scandinavian descent with the strongest signal for rs1876487 (odds ratio = 0.82; p value = 0.003). Interestingly, families which were used to map the PARK3 locus, have Scandinavian ancestry suggesting a founder effect. In conclusion, this large association study for the SPR gene revealed no association for PD worldwide. However, taking the initial mapping of the PARK3 into account, the role of a population-specific effect warrants consideration in future studies.

KW - PARK3

KW - Parkinson disease

KW - PD genetic studies

KW - PD-GWAS

KW - SPR

UR - http://www.scopus.com/inward/record.url?scp=80052624072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052624072&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2011.05.024

DO - 10.1016/j.neurobiolaging.2011.05.024

M3 - Article

C2 - 21782285

AN - SCOPUS:80052624072

VL - 32

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 11

ER -